Analytical Data
-
Gene name
pscF
- Application
-
Alternative Names
Pseudomonas secretion protein F
-
Species
Pseudomonas aeruginosa
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P95434
-
Expression Region
2-85aa
-
Molecular Weight
16.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The recombinant protein PSCF (Pulmonary Surfactant-Associated Protein F) has garnered significant attention in recent years due to its crucial role in lung function and surfactant homeostasis. PSCF is part of a family of proteins that are essential for reducing surface tension in the alveoli, which prevents lung collapse and facilitates efficient gas exchange. Its dysfunction is associated with various respiratory diseases, including Acute Respiratory Distress Syndrome (ARDS) and neonatal respiratory distress syndrome. Research into PSCF aims to better understand its structural and functional properties, along with its interactions with other surfactant proteins and lipids. Studies have focused on the recombinant expression of PSCF in various systems to produce sufficient quantities for biochemical and functional assays. Additionally, investigations are being conducted to explore the therapeutic potential of PSCF in treating pulmonary disorders, leveraging its properties to enhance surfactant replacement therapies. This research is further supported by advancements in genetic engineering techniques, allowing for the design of PSCF variants with improved stability and activity. Overall, the study of PSCF and its recombinant forms is pivotal for developing novel therapeutic strategies to address pulmonary diseases, ultimately contributing to improved patient outcomes and insights into the underlying mechanisms of surfactant biology.
